BioNTech (NASDAQ:BNTX) Price Target Increased to $132.00 by Analysts at TD Cowen

BioNTech (NASDAQ:BNTX) had its price target upped by analysts at TD Cowen from $85.00 to $132.00 in a research note issued on Monday, Benzinga reports. The firm presently has a “hold” rating on the stock. TD Cowen’s price target indicates a potential upside of 19.98% from the stock’s current price.

A number of other equities research analysts also recently commented on the stock. Bank of America lifted their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Morgan Stanley upgraded BioNTech from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and lifted their price objective for the company from $96.00 to $150.00 in a research note on Tuesday, September 17th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, HSBC lifted their price target on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and a consensus price target of $135.54.

BioNTech Price Performance

Shares of BNTX traded down $1.75 on Monday, reaching $110.02. The stock had a trading volume of 92,439 shares, compared to its average volume of 785,807. The firm has a 50-day moving average of $104.56 and a 200 day moving average of $94.20. The firm has a market capitalization of $26.15 billion, a PE ratio of 219.42 and a beta of 0.24. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s revenue for the quarter was down 23.3% on a year-over-year basis. During the same period last year, the company posted ($0.86) EPS. Sell-side analysts expect that BioNTech will post -3.04 EPS for the current year.

Institutional Trading of BioNTech

Several hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after buying an additional 150 shares during the last quarter. Covestor Ltd grew its position in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the period. EverSource Wealth Advisors LLC lifted its position in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. Finally, Crewe Advisors LLC bought a new position in BioNTech in the 1st quarter worth about $75,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.